# Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Canonical URL: https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-of-kresladitm-for-the-treatment-of-severe-leukocyte-adhesion-deficiency-i-lad-i
Ticker: RCKT
Company: Rocket Pharmaceuticals
Source: Rocket Pharmaceuticals
Published: 2025-10-14 11:00 EST
Original Source URL: https://ir.rocketpharma.com
## Summary

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026 All primary and secondary endpoints were met, and KRESLADI™ was well tolerated Rocket is eligible for a Rare Pediatric Disease Priority Review Voucher, should KRESLADI ™ be approved CRANBURY, N.J. --(BUSINESS WIRE)--Oct.

## Article Body
Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026 All primary and secondary endpoints were met, and KRESLADI™ was well tolerated Rocket is eligible for a Rare Pediatric Disease Priority Review Voucher, should KRESLADI ™ be approved CRANBURY, N.J. --(BUSINESS WIRE)--Oct.
## Recent Company News
- 2026-05-07 20:00 EST — [Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
- 2026-04-28 11:00 EST — [Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-180-million-sale-of-priority-review-voucher) — Source: Rocket Pharmaceuticals
- 2026-03-27 11:00 EST — [Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-approval-of-kresladitm-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i) — Source: Rocket Pharmaceuticals
- 2026-02-26 21:00 EST — [Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
- 2026-02-23 12:00 EST — [Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Rocket Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)